Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 10, 2006, Pages 1068-1079

  Kaufmann, Stefan H E ^a   Baumann, S ^a   Eddine, A Nasser ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

BCG; Macrophages; T cells; Vaccine

Indexed keywords

BCG VACCINE; DNA VACCINE; RECOMBINANT PROTEIN; SUBUNIT VACCINE;

ADJUVANT THERAPY; BACTERIAL STRAIN; BCG VACCINATION; CELL PROTECTION; CLINICAL TRIAL; DEFENSE MECHANISM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MACROPHAGE; MOLECULAR GENETICS; MYCOBACTERIUM BOVIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; T LYMPHOCYTE; TUBERCULOSIS; VACCINIA VIRUS; VIRUS RECOMBINANT;

BCG VACCINE; EPITOPES; HUMANS; IMMUNITY, CELLULAR; LUNG; MACROPHAGES; MOLECULAR BIOLOGY; T-LYMPHOCYTES; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 33749476080     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Flynn J L, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-129.
2. Geijtenbeek TBH, van Vliet S J, Koppel E A, et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2003; 197: 7-17.
3. Schaible U E, Winau F, Sieling P A, et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 2003; 9: 1039-1046.
4. Pedrazzini T, Hug K, Louis J A. Importance of L3T4+ and Lyt-2+ cells in the immunological control of infection with Mycobacterium bovis strain Bacillus Calmette-Guerin in mice-assessment by elimination of T-cell subsets in vivo. J Immunol 1987; 139: 2032-2037.
5. Muller I, Cobbold S P, Waldmann H, Kaufmann S H E. Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T-Cells. Infect Immun 1987; 55: 2037-2041.
6. Kaufmann S H E. Gamma/delta and other unconventional T lymphocytes: what do they see and what do they do? Proc Natl Acad Sci U S A 1996; 93: 2272-2279.
7. Shen L, Shen Y, Huang D, et al. Development of V gamma 2V delta 2(+) T cell responses during active mycobacterial coinfection of simian immunodeficiency virus-infected macaques requires control of viral infection and immune competence of CD4(+) T cells. J Infect Dis 2004; 190: 1438-1447.
8. Roura-Mir C, Moody D B. Sorting out self and microbial lipid antigens for CD1. Microbes Infect 2003; 5: 1137-1148.
9. Fischer K, Scotet E, Niemeyer M, et al. Mycobacterial phosphatidylinositol mannoside is a natural antigen for old-restricted T cells. Proc Natl Acad Sci USA 2004; 101: 10685-10690.
10. Flynn J L, Chan J. Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr Opin Immunol 2003; 15: 450-455.
11. Raupach B, Kaufmann S H E. Immune responses to intracellular bacteria. Curr Opin Immunol 2001; 13: 417-428.
12. Hingley-Wilson S M, Sambandamurthy V K, Jacobs W R. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nat Immunol 2003; 4: 949-955.
13. Schaible U E, Kaufmann S H E. Iron and microbial infection. Nat Rev Micro 2004; 2: 946-953.
14. Ferrari G, Langen H, Naito M, Pieters J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 1999; 97: 435-447.
15. Reyrat J, Berthet F, Gicquel B. The urease locus of Mycobacterium tuberculosis and its utilization for the demonstration of allelic exchange in Mycobacterium bovis Bacillus Calmette-Guerin. Proc Natl Acad Sci U S A 1995; 92: 8768-8772.
16. Gutierrez M G, Master S S, Singh S B, et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004; 119: 753-766.
17. MacMicking J D, Taylor G A, McKinney J D. Immune control of tuberculosis by IFN-(gamma)-inducible LRG-47. Science 2003; 302: 654-659.
18. Kaufmann S H. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001; 1: 20-30.
19. Kaufmann S H E, McMichael A J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 2005; 11: 33-44.
20. Sorensen A L, Nagai S, Houen G, Andersen P, Andersen A B. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 1995; 63: 1710-1717.
21. Berthet F X, Rasmussen P B, Rosenkrands I, Andersen P, Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 1998; 144: 3195-3203.
22. Mahairas G G, Sabo P J, Hickey M J, Singh D C, Stover C K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996; 178: 1274-1282.
23. Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2: 893-898.
24. Mollenkopf H J, Grode L, Mattow J, et al. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infect Immun 2004; 72: 6471-6479.
25. Brandt L, Elhay M, Rosenkrands I, Lindblad E B, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000; 68: 791-795.
26. McShane H, Brookes R, Gilbert S C, Hill AVS. Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001; 69: 681-686.
27. Tanghe A, Denis O, Lambrecht B, et al. Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment. Infect Immun 2000; 68: 3854-3860.
28. Cai H, Tian X, Hu X D, Zhuang Y H, Zhu Y X. Combined DNA vaccines formulated in DDA enhance protective immunity against tuberculosis. DNA Cell Biol 2004; 23: 450-456.
29. Hess J, Kaufmann S H E. Live antigen carriers as tools for improved anti-tuberculosis vaccines. FEMS Immunol Med Microbiol 1999; 23: 165-173.
30. Horwitz M A, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003; 71: 1672-1679.
31. Olsen A W, Williams A, Okkels L M, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004; 72: 6148-6150.
32. Nagai S, Wiker H G, Harboe M, Kinomoto M. Isolation and partial characterization of major protein antigens in the culture fluid of Mycobacterium tuberculosis. Infect Immun 1991; 59: 372-382.
33. Delogu G, Howard A, Collins F M, Morris S L. DNA vaccination against tuberculosis: Expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun 2000; 68: 3097-3102.
34. Brodin P, Majlessi L, Brosch R, et al. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. J Infect Dis 2004; 190: 115-122.
35. Majlessi L, Rojas M J, Brodin P, Leclerc C. CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family. Infect Immun 2003; 71: 7173-7177.
36. Skjot RLV, Brock I, Arend S M, et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 2002; 70: 5446-5453.
37. Coler R N, Campos-Neto A, Ovendale P, et al. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J Immunol 2001; 166: 6227-6235.
38. Agrewala J N, Wilkinson R J. Differential regulation of Th1 and Th2 cells by p91-110 and p21-40 peptides of the 16-kD alpha-crystallin antigen of Mycobacterium tuberculosis. Clin Exp Immunol 1998; 114: 392-397.
39. Lowrie D B, Tascon R E, Bonato V L D, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400: 269-271.
40. Tascon R E, Colston M J, Ragno S, et al. Vaccination against tuberculosis by DNA injection. Nat Med 1996; 2: 888-892.
41. Bhaskar S, Khanna S P, Mukherjee R. Isolation, purification and immunological characterization of novel low molecular weight protein antigen CFP 6 from culture filtrate of M. tuberculosis. Vaccine 2000; 18: 2856-2866.
42. Webb J R, Vedvick T S, Alderson M R, et al. Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis. Infect Immun 1998; 66: 4208-4214.
43. Al Attiyah R, Mustafa A S, Abal A T, et al. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin Exp Immunol 2004; 138: 139-144.
44. Alderson M R, Bement T, Day C H, et al. Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells. J Exp Med 2000; 191: 551-559.
45. Skeiky YAW, Lodes M J, Guderian J A, et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun 1999; 67: 3998-4007.
46. Tanghe A, Lefevre P, Denis O, et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J Immunol 1999; 162: 1113-1119.
47. Rao V, Dhar N, Tyagi A K. Modulation of host immune responses by overexpression of immunodominant antigens of Mycobacterium tuberculosis in bacille Calmette-Guerin. Scand J Immunol 2003; 58: 449-461.
48. Skeiky YAW, Alderson M R, Ovendale P J, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004; 172: 7618-7628.
49. Dillon D C, Alderson M R, Day C H, et al. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun 1999; 67: 2941-2950.
50. Skeiky YAW, Ovendale P J, Jen S, et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control infection. J Immunol 2000; 165: 7140-7149.
51. Xue T, Stavropoulos E, Yang M, et al. RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection. Infect Immun 2004; 72: 6324-6329.
52. Hewinson R G, Michell S L, Russell W P, McAdam R A, Jacobs W R. Molecular characterization of MPT83: A seroreactive antigen of Mycobacterium tuberculosis with homology to MPT70. Scand J Immunol 1996; 43: 490-499.
53. Dhiman N, Khuller G K. Immunoprophylactic properties of 71-kDa cell wall-associated protein antigen of Mycobacterium tuberculosis H37Ra. Med Microbiol Immunol 1997; 186: 45-51.
54. Dhiman N, Khuller G K. Protective efficacy of mycobacterial 71-kDa cell wall associated protein using poly (DL-lactide-coglycolide) microparticles as carrier vehicles. FEMS Immunol Med Microbiol 1998; 21: 19-28.
55. Okkels L M, Brock I, Follmann F, et al. PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: Strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family. Infect Immun 2003; 71: 6116-6123.
56. Demangel C, Brodin P, Cockle P J, et al. Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6. Infect Immun 2004; 72: 2170-2176.
57. Al Attiyah R, Mustafa A S. Computer-assisted prediction of HLA-DR binding and experimental analysis for human promiscouos Th1-cell peptides in the 24 kDa secreted lipoprotein (LppX) of Mycobacterium tuberculosis. Scand J Immunol 2004; 59: 16-24.
58. Temmerman S, Pethe K, Parra M, et al. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med 2004; 10: 935-941.
59. Agger E M, Brock I, Okkels L M, et al. Human T-cell responses to the RD1-encoded protein TB27.4 (Rv3878) from Mycobacterium tuberculosis. Immunology 2003; 110: 507-512.
60. Olsen A W, van Pinxteren LAH, Okkels L M, Rasmussen P B, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of Antigen 85B and ESAT-6. Infect Immun 2001; 69: 2773-2778.
61. Brandt L, Skeiky YAW, Alderson M R, et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M.tuberculosis-infected guinea pigs. Infect Immun 2004; 72: 6622-6632.
62. Parra M, Pickett T, Delogu G, et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun 2004; 72: 6799-6805.
63. Temmerman S T, Place S, Debrie A S, Locht C, Mascart F. Effector functions of heparin-binding hemagglutinin-specific CD8(+) T lymphocytes in latent human tuberculosis. J Infect Dis 2005; 192: 226-232.
64. Turner J, Rhoades E R, Keen M, et al. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 2000; 68: 1706-1709.
65. Voskuil M I, Schnappinger D, Visconti K C, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 2003; 198: 705-713.
66. Ying Y A, Crane D D, Barry C E. Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. J Bacteriol 1996; 178: 4484-4492.
67. Monahan I M, Betts J, Banerjee D K, Butcher P D. Differential expression of mycobacterial proteins following phagocytosis by macrophages. Microbiology-Sgm 2001; 147: 459-471.
68. Florczyk M A, Mccue L A, Stack R F, Hauer C R, McDonough K A. Identification and characterization of mycobacterial proteins differentially expressed under standing and shaking culture conditions, including Rv2623 from a novel class of putative ATP-binding proteins. Infect Immun 2001; 69: 5777-5785.
69. Boon C, Li R, Qi R, Dick T. Proteins of Mycobacterium bovis BCG induced in the Wayne dormancy model. J Bacteriol 2001; 183: 2672-2676.
70. Feige U, van Eden W. Infection, autoimmunity and autoimmune disease. EXS 1996; 77: 359-373.
71. Santos-Junior R R, Sartori A, Franco M D, et al. Immunomodulation and protection induced by DNA-hsp65 vaccination in an animal model of arthritis. Hum Gene Ther 2005; 16: 1338-1345.
72. Downing K J, Betts J C, Young D I, et al. Global expression profiling of strains harbouring null mutations reveals that the five rpf-like genes of Mycobacterium tuberculosis show functional redundancy. Tuberculosis 2004; 84: 167-179.
73. Peppoloni S, Ruggiero P, Contorni M, et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines 2003; 2: 285-293.
74. McShane H, Pathan A A, Sander C R, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10: 1240-1244.
75. Gurunathan S, Klinman D M, Seder R A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000; 18: 927-974.
76. Macgregor R R, Boyer J D, Ugen K E, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178: 92-100.
77. Stittelaar K J, Kuiken T, de Swart R L, et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 2001; 19: 3700-3709.
78. Brewer J M, Conacher M, Hunter C A, et al. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4-or IL-13-mediated signaling. J Immunol 1999; 163: 6448-6454.
79. Lindblad E B, Elhay M J, Silva R, Appelberg R, Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 1997; 65: 623-629.
80. Ling I T, Ogun S A, Momin P, et al. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. Vaccine 1997; 15: 1562-1567.
81. Jacobsen M, Repsilber D, Gutschmidt A, et al. Ras-associated small GTPase 33A, a novel T cell factor, is down-regulated in patients with tuberculosis. J Infect Dis 2005; 192: 1211-1218.
82. Kita Y, Tanaka T, Yoshida S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey. Vaccine 2005; 23: 2132-2135.
83. Lingnau K, Egyed A, Schellack C, et al. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 2002; 20: 3498-3508.
84. Goonetilleke N P, McShane H, Hannan C M, et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003; 171: 1602-1609.
85. Bowe F, Lavelle E C, McNeela E A, et al. Mucosal vaccination against serogroup B meningococci: Induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect Immun 2004; 72: 4052-4060.
86. Mutsch M, Zhou W G, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350: 896-903.
87. Cole S T. Learning from the genome sequence of Mycobacterium tuberculosis H37Rv. FEBS Letters 1999; 452: 7-10.
88. Rachman H, Strong M, Ulrichs T, et al. Unique transcriptome signature of Mycobacterium tuberculosis in pulmonary tuberculosis. Infect Immun 2005; 74: 1233-1242.
89. Jackson M, Phalen S W, Lagranderie M, et al. Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect Immun 1999; 67: 2867-2873.
90. Hondalus M K, Bardarov S, Russell R, et al. Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect Immun 2000; 68: 2888-2898.
91. Smith D A, Parish T, Stoker N G, Bancroft G J. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 2001; 69: 1142-1150.
92. Tullius M V, Harth G, Horwitz M A. Glutamine synthetase GInA1 is essential for growth of Mycobacterium tuberculosis in human THP-1 macrophages and guinea pigs. Infect Immun 2003; 71: 3927-3936.
93. Pavelka M S Jr, Chen B, Kelley C L, Collins F M, Jacobs W R Jr. Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis. Infect Immun 2003; 71: 4190-4192.
94. Sambandamurthy V K, Wang X, Chen B, et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 2002; 8: 1171-1174.
95. Hsu T, Hingley-Wilson S M, Chen B, et al. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. PNAS 2003; 100: 12420-12425.
96. Berthet F, Lagranderie M, Gounon P, et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erpg. Science 1998; 282: 759-762.
97. Braunstein M, Espinosa B J, Chan J, Belisle J T, Jacobs R. SecA2 functions in the secretion of superoxide dismutase A and in the virulence of Mycobacterium tuberculosis. Mol Microbiol 2003; 48: 453-464.
98. Perez E, Samper S, Bordas Y, et al. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 2001; 41: 179-187.
99. Edwards K M, Cynamon M H, Voladri R K, et al. Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2001; 164: 2213-2219.
100. Pethe K, Alonso S, Biet F, et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 2001; 412(6843): 190-194.
101. Hess J, Miko D, Catic A, et al. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci U S A 1998; 95: 5299-5304.
102. Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005; 115: 2472-2479.
103. Murray P J, Aldovini A, Young R A. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci U S A 1996; 93(2): 934-939.
104. Horwitz M A, Harth G, Dillon B J, Maslesa-Galic' S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 2000; 97: 13853-13858.
105. Pym A S, Brodin P, Majlessi L, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003; 9: 533-539.
106. Guleria I, Teitelbaum R, McAdam R A, et al. Auxotrophic vaccines for tuberculosis. Nat Med 1996; 2(3): 334-337.
107. Kaufmann S H E. Immunity to intracellular bacteria. Annu Rev Immunol 1993; 11: 129-163.
108. Chackerian A A, Perera T V, Behar S M. Gamma interferon-producing CD4+ T Lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis. Infect Immun 2001; 69: 2666-2674.
109. Pancholi P, Mirza A, Bhardwaj N, Steinman R M. Sequestration from immune CD4+ T cells of mycobacteria growing in human macrophages. Science 2004; 260: 984-986.
110. Glomski IJ, Gedde M M, Tsang A W, Swanson J A, Portnoy D A. The Listeria monocytogenes hemolysin has an acidic pH optimum to compartmentalize activity and prevent damage to infected host cells. J Cell Biol 2002; 156: 1029-1038.
111. Moors M A, Levitt B, Youngman P, Portnoy D A. Expression of listeriolysin O and ActA by intracellular and extracellular Listeria monocytogenes. Infect Immun 1999; 67: 131-139.
112. Sturgill-Koszycki S, Haddix P L, Russell D G. The interaction between Mycobacterium and the macrophage analyzed by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1997; 18: 2558-2565.
113. Glynn J R, Whiteley J, Bifani P J, Kremer K, van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 2002; 8: 843-849.
114. Nasser Eddine A, Kaufmann S H E. Improved protection by recombinant BCG. Microbes Infect 2005; 7: 939-946.
115. Rogers H W, Callery M P, Deck B, Unanue E R. Listeria monocytogenes induces apoptosis of infected hepatocytes. J Immunol 1996; 156: 679-684.
116. Lee K D, Oh Y K, Portnoy D A, Swanson J A. Delivery of macromolecules into cytosol using liposomes containing hemolysin from Listeria monocytogenes. J Biol Chem 1996; 271: 7249-7252.
117. Cirman T, Oresic K, Mazovec G D, et al. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of bid by multiple papain-like lysosomal cathepsins. J Biol Chem 2004; 279: 3578-3587.
118. Behr M A, Wilson M A, Gill W P, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284: 1520-1523.
119. Talbot E A, Perkins M D, Silva SFM, Frothingham R. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 1997; 24: 1139-1146.
120. Von Reyn C F, Clements C J, Mann J M. Human immunodeficiency virus-infection and routine childhood immunization. Lancet 1987; 2: 669-672.
121. Mills J W, Ryan L, LaCourse R, North R J. Extensive Mycobacterium bovis BCG infection of liver parenchymal cells in immunocompromised mice. Infect Immun 2001; 69: 3175-3180.
122. Horwitz M A. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect 2005; 7: 947-954.